Literature DB >> 22962688

Human herpesvirus 6 latent infection in patients with glioma.

Jing Chi1, Bin Gu, Chun Zhang, Guangyong Peng, Feng Zhou, Yun Chen, Guofeng Zhang, Yidi Guo, Dandan Guo, Jian Qin, Jinfeng Wang, Lingyun Li, Fang Wang, Genyan Liu, Fangyi Xie, Dongju Feng, Hong Zhou, Xingxu Huang, Shiqiang Lu, Yingxia Liu, Weixing Hu, Kun Yao.   

Abstract

The etiology of glioma remains unclear so far. Human herpesvirus 6 (HHV-6) might be associated with glioma, but there is no direct evidence to support this. High percentages of HHV-6 DNA and protein were detected in tissue from gliomas, compared with normal brain tissue. In addition, a strain of HHV-6A was isolated from the fluid specimens from glioma cysts. High levels of interleukin 6 (IL-6), interleukin 8 (IL-8), tumor necrosis factor α, and transforming growth factor β (TGF-β) were detected in the cyst fluid specimens from HHV-6-positive patients with glioma. Furthermore, HHV-6A infection promoted IL-6, IL-8, and TGF-β production in astrocyte cultures. Our studies strongly suggest the involvement of HHV-6 infection in the pathogenesis of glioma.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22962688     DOI: 10.1093/infdis/jis513

Source DB:  PubMed          Journal:  J Infect Dis        ISSN: 0022-1899            Impact factor:   5.226


  20 in total

Review 1.  The role of the RTEL1 rs2297440 polymorphism in the risk of glioma development: a meta-analysis.

Authors:  Cuiping Zhang; Yu Lu; Xiaolian Zhang; Dongmei Yang; Shuxin Shang; Denghe Liu; Kongmei Jiang; Weiqiang Huang
Journal:  Neurol Sci       Date:  2016-03-03       Impact factor: 3.307

2.  Prevalence of Neurotropic Viruses in Malignant Glioma and Their Onco-Modulatory Potential.

Authors:  Tadej Strojnik; Darja Duh; Tamara T Lah
Journal:  In Vivo       Date:  2017 Mar-Apr       Impact factor: 2.155

3.  Human herpesvirus 6A infection in CD46 transgenic mice: viral persistence in the brain and increased production of proinflammatory chemokines via Toll-like receptor 9.

Authors:  Joséphine M Reynaud; Jean-François Jégou; Jérémy C Welsch; Branka Horvat
Journal:  J Virol       Date:  2014-02-26       Impact factor: 5.103

Review 4.  Classification of HHV-6A and HHV-6B as distinct viruses.

Authors:  Dharam Ablashi; Henri Agut; Roberto Alvarez-Lafuente; Duncan A Clark; Stephen Dewhurst; Dario DiLuca; Louis Flamand; Niza Frenkel; Robert Gallo; Ursula A Gompels; Per Höllsberg; Steven Jacobson; Mario Luppi; Paolo Lusso; Mauro Malnati; Peter Medveczky; Yasuko Mori; Philip E Pellett; Joshua C Pritchett; Koichi Yamanishi; Tetsushi Yoshikawa
Journal:  Arch Virol       Date:  2013-11-06       Impact factor: 2.574

5.  Development of virus-specific CD4+ and CD8+ regulatory T cells induced by human herpesvirus 6 infection.

Authors:  Fang Wang; Jing Chi; Guangyong Peng; Feng Zhou; Jinfeng Wang; Lingyun Li; Dongju Feng; Fangyi Xie; Bin Gu; Jian Qin; Yun Chen; Kun Yao
Journal:  J Virol       Date:  2013-11-06       Impact factor: 5.103

6.  Immunomodulation and immunosuppression by human herpesvirus 6A and 6B.

Authors:  Lorenzo Dagna; Joshua C Pritchett; Paolo Lusso
Journal:  Future Virol       Date:  2013-03       Impact factor: 1.831

7.  Human Herpesvirus 6A U14 Is Important for Virus Maturation.

Authors:  Junko Mori; Huamin Tang; Akiko Kawabata; Masato Koike; Yasuko Mori
Journal:  J Virol       Date:  2015-11-11       Impact factor: 5.103

Review 8.  The Association of Human Herpesviruses with Malignant Brain Tumor Pathology and Therapy: Two Sides of a Coin.

Authors:  Evita Athanasiou; Antonios N Gargalionis; Fotini Boufidou; Athanassios Tsakris
Journal:  Int J Mol Sci       Date:  2021-02-24       Impact factor: 5.923

9.  Features of Human Herpesvirus-6A and -6B Entry.

Authors:  Takahiro Maeki; Yasuko Mori
Journal:  Adv Virol       Date:  2012-10-23

10.  Implication of human herpesviruses in oncogenesis through immune evasion and supression.

Authors:  Kenneth Alibek; Yeldar Baiken; Ainur Kakpenova; Assel Mussabekova; Samal Zhussupbekova; Madina Akan; Bolat Sultankulov
Journal:  Infect Agent Cancer       Date:  2014-01-20       Impact factor: 2.965

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.